A Novel Therapy for Presbycusis

Hearing amplification is the mainstay of treatment for presbycusis, but adherence with this therapy remains abysmally low, necessitating the exploration of other treatment modalities. Mineralocorticoids represent one such novel treatment modality. Although research on mineralocorticoids to prevent and retard presbycusis in humans shows promise and the potential to radically change the way clinicians approach age-related hearing loss, it remains in its infancy. Future studies that further evaluate the safety and efficacy of mineralocorticoids for presbycusis are still required for this potentially paradigm shifting therapy to gain widespread acceptance.